TrialInternational journal of cancer2018

Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.

Meixia Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.